Literature DB >> 10525657

Mutants of glucokinase cause hypoglycaemia- and hyperglycaemia syndromes and their analysis illuminates fundamental quantitative concepts of glucose homeostasis.

E A Davis1, A Cuesta-Muñoz, M Raoul, C Buettger, I Sweet, M Moates, M A Magnuson, F M Matschinsky.   

Abstract

AIMS/HYPOTHESIS: Mutations of the glucokinase gene cause hyperglycaemia or hypoglycaemia. A quantitative understanding of these defects of glucose homeostasis linked to the glucokinase gene was lacking. Therefore a database of kinetic variables of wild-type and 20 missense mutants of glucokinase was developed and used in mathematical modelling to predict the thresholds for glucose-stimulated insulin release.
METHODS: Recombinant human glucokinase was generated in E. coli. The k(cat), glucose S(0.5), ATP K(m), and Hill number of glucokinase were determined. Inhibition by Stearoyl CoA and glucokinase regulatory protein and thermal stability were assayed for all mutants kinetically similar to wild-type glucokinase. A mathematical model predicting the threshold for glucose-stimulated insulin release was constructed. This model is based on the two substrate kinetics of glucokinase and the kinetic variables of the database. It is assumed that both glucokinase gene alleles are equally expressed in beta-cells and that induction of glucokinase occurs as a function of basal blood glucose.
RESULTS: Large changes, varying greatly between mutants were found in nearly all variables. Glucokinase flux at threshold for glucose-stimulated insulin release was about 25 % of total phosphorylating potential in the normal beta-cell and this was used to predict thresholds for the mutant heterozygotes. Clinical data for maturity onset diabetes of the young type linked to the glucokinase gene and familial hyperinsulinaemic hypoglycaemia linked to the glucokinase gene and the glucokinase kinetic data of this study were used to test the model. The model predicts fasting blood glucose between 3 and 7 mmol/l in these cases. CONCLUSION/
INTERPRETATION: A kinetics database of wild-type and 20 mutants of glucokinase was developed. Many kinetic differences were found for the mutants. The mathematical model to calculate the threshold for glucose-stimulated insulin release predicts fasting blood glucose between 3 and 7 mmol/l in subjects with glucokinase gene mutations. [Diabetologia 42: 1175-1186]

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10525657     DOI: 10.1007/s001250051289

Source DB:  PubMed          Journal:  Diabetologia        ISSN: 0012-186X            Impact factor:   10.122


  52 in total

1.  Thermal stability of glucokinase (GK) as influenced by the substrate glucose, an allosteric glucokinase activator drug (GKA) and the osmolytes glycerol and urea.

Authors:  B Zelent; C Buettger; J Grimsby; R Sarabu; J M Vanderkooi; A J Wand; F M Matschinsky
Journal:  Biochim Biophys Acta       Date:  2012-03-16

2.  Association with nitric oxide synthase on insulin secretory granules regulates glucokinase protein levels.

Authors:  Michele L Markwardt; Andongfac Nkobena; Shi-Ying Ding; Mark A Rizzo
Journal:  Mol Endocrinol       Date:  2012-07-06

Review 3.  Mutations in pancreatic ß-cell Glucokinase as a cause of hyperinsulinaemic hypoglycaemia and neonatal diabetes mellitus.

Authors:  Khalid Hussain
Journal:  Rev Endocr Metab Disord       Date:  2010-09       Impact factor: 6.514

4.  Determinants of human glucokinase activation and implications for small molecule allosteric control.

Authors:  Quinn Li; Lokesh Gakhar; M Ashley Spies
Journal:  Biochim Biophys Acta Gen Subj       Date:  2018-06-06       Impact factor: 3.770

5.  GCK-MODY in the US National Monogenic Diabetes Registry: frequently misdiagnosed and unnecessarily treated.

Authors:  David Carmody; Rochelle N Naylor; Charles D Bell; Shivani Berry; Jazzmyne T Montgomery; Elizabeth C Tadie; Jessica L Hwang; Siri Atma W Greeley; Louis H Philipson
Journal:  Acta Diabetol       Date:  2016-04-22       Impact factor: 4.280

6.  Tryptophan Fluorescence Yields and Lifetimes as a Probe of Conformational Changes in Human Glucokinase.

Authors:  Bogumil Zelent; Chris Bialas; Ignacy Gryczynski; Pan Chen; Rahul Chib; Karina Lewerissa; Maria G Corradini; Richard D Ludescher; Jane M Vanderkooi; Franz M Matschinsky
Journal:  J Fluoresc       Date:  2017-04-22       Impact factor: 2.217

Review 7.  Pharmacokinetic/pharmacodynamic modelling in diabetes mellitus.

Authors:  Cornelia B Landersdorfer; William J Jusko
Journal:  Clin Pharmacokinet       Date:  2008       Impact factor: 6.447

8.  Structure-based predictive models for allosteric hot spots.

Authors:  Omar N A Demerdash; Michael D Daily; Julie C Mitchell
Journal:  PLoS Comput Biol       Date:  2009-10-09       Impact factor: 4.475

9.  Clinical heterogeneity in monogenic diabetes caused by mutations in the glucokinase gene (GCK-MODY).

Authors:  Antonio L Cuesta-Muñoz; Tiinamaija Tuomi; Nadia Cobo-Vuilleumier; Hanna Koskela; Stella Odili; Amanda Stride; Carol Buettger; Timo Otonkoski; Philippe Froguel; Joseph Grimsby; Maria Garcia-Gimeno; Franz M Matschinsky
Journal:  Diabetes Care       Date:  2009-11-10       Impact factor: 19.112

Review 10.  Molecular physiology of mammalian glucokinase.

Authors:  P B Iynedjian
Journal:  Cell Mol Life Sci       Date:  2009-01       Impact factor: 9.261

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.